C5 and hemolytic-uremic syndrome: When detected, they normally respond well to terminal complement inhibition via the C5 inhibitor eculizumab.7 Our studies support the notion that podocyte-to-GEnC crosstalk also activates the complement cascade early in the much more common form of HUS driven by Stx.